John J. Weroha

Dr. John J. Weroha is an Associate Professor of Oncology at Mayo Clinic, with affiliations in the Department of Oncology and Mayo Clinic Comprehensive Cancer Center. He specializes in gynecologic malignancies and phase 1 clinical trials, focusing on personalized cancer therapy using patient-derived xenografts (PDX) and molecular targeted therapies. Dr. Weroha holds academic ranks in Oncology, Pharmacology, and Medicine.

• Academic Roles: Associate Professor of Oncology, Mayo Clinic College of Medicine
• Clinical Focus: Gynecologic oncology, phase 1 trials, and precision medicine
• Institutional Affiliations: Mayo Clinic Comprehensive Cancer Center, Mayo Medical School

Education

• MD: University of Kansas School of Medicine (2007)
• PhD: University of Kansas School of Medicine (2007), Pharmacology, Toxicology & Therapeutics
• BS: University of Kansas (1998), Cellular Biology
• Fellowship: Hematology/Oncology, Mayo School of Graduate Medical Education (2013)

Research Interests

Dr. Weroha's research bridges laboratory innovations with clinical applications, emphasizing:

• Development of novel therapeutic combinations for ovarian cancer
• Mechanisms of resistance to PARP inhibitors
• Use of PDX models to predict treatment responses
• Strategies for overcoming therapeutic resistance
• Integration of next-generation sequencing for personalized therapy

Scientific Contributions

His work has advanced understanding of:

• PARP inhibitor mechanisms in ovarian cancer
• Senolytics' role in aging and disease
• Molecular pathways driving metastasis

Awards & Honors

• Top 20% Mayo Clinic Department of Medicine Teaching Faculty (2014)
• Chief Clinical Investigator, Mayo Graduate School (2010)
• Multiple honors for academic excellence (1998–2005)

Clinical & Professional Roles

Dr. Weroha leads:

• Mayo Clinic Ovarian Cancer SPORE (2015–present)
• Translational Science Program, Mayo Clinic Comprehensive Cancer Center (2023–present)
• Professional memberships: AACR, ASCO, Society of Gynecologic Oncologists